These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 19638206

  • 1. PIK3CA alterations in Middle Eastern ovarian cancers.
    Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, Uddin S, Al-Kuraya KS.
    Mol Cancer; 2009 Jul 28; 8():51. PubMed ID: 19638206
    [Abstract] [Full Text] [Related]

  • 2. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
    Yip WK, Choo CW, Leong VC, Leong PP, Jabar MF, Seow HF.
    APMIS; 2013 Oct 28; 121(10):954-66. PubMed ID: 23992303
    [Abstract] [Full Text] [Related]

  • 3. PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.
    Agell L, Hernández S, Salido M, de Muga S, Juanpere N, Arumí-Uria M, Menendez S, Lorenzo M, Lorente JA, Serrano S, Lloreta J.
    Mod Pathol; 2011 Mar 28; 24(3):443-52. PubMed ID: 21113138
    [Abstract] [Full Text] [Related]

  • 4. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.
    Acta Oncol; 2014 Jul 28; 53(7):852-64. PubMed ID: 24666267
    [Abstract] [Full Text] [Related]

  • 5. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
    Catasus L, Gallardo A, Cuatrecasas M, Prat J.
    Mod Pathol; 2009 Apr 28; 22(4):522-9. PubMed ID: 19234438
    [Abstract] [Full Text] [Related]

  • 6. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
    Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R.
    PLoS One; 2011 Apr 28; 6(7):e22769. PubMed ID: 21829508
    [Abstract] [Full Text] [Related]

  • 7. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
    Cossu-Rocca P, Orrù S, Muroni MR, Sanges F, Sotgiu G, Ena S, Pira G, Murgia L, Manca A, Uras MG, Sarobba MG, Urru S, De Miglio MR.
    PLoS One; 2015 Apr 28; 10(11):e0141763. PubMed ID: 26540293
    [Abstract] [Full Text] [Related]

  • 8. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
    Bosse T, ter Haar NT, Seeber LM, v Diest PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H, Smit VT.
    Mod Pathol; 2013 Nov 28; 26(11):1525-35. PubMed ID: 23702729
    [Abstract] [Full Text] [Related]

  • 9. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
    Suda T, Hama T, Kondo S, Yuza Y, Yoshikawa M, Urashima M, Kato T, Moriyama H.
    BMC Cancer; 2012 Sep 20; 12():416. PubMed ID: 22994622
    [Abstract] [Full Text] [Related]

  • 10. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
    Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, Al-Sanea O, Al-Dayel F, Uddin S, Al-Kuraya KS.
    J Clin Endocrinol Metab; 2008 Feb 20; 93(2):611-8. PubMed ID: 18000091
    [Abstract] [Full Text] [Related]

  • 11. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN, Lin MC, Huang WC, Chiang YC, Kuo KT.
    Mod Pathol; 2014 Jul 20; 27(7):983-90. PubMed ID: 24336158
    [Abstract] [Full Text] [Related]

  • 12. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
    Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R.
    Mol Cancer Ther; 2011 Mar 20; 10(3):558-65. PubMed ID: 21216929
    [Abstract] [Full Text] [Related]

  • 13. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
    Lee S, Choi EJ, Jin C, Kim DH.
    Gynecol Oncol; 2005 Apr 20; 97(1):26-34. PubMed ID: 15790433
    [Abstract] [Full Text] [Related]

  • 14. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.
    Martin V, Botta F, Zanellato E, Molinari F, Crippa S, Mazzucchelli L, Frattini M.
    Histol Histopathol; 2012 Jun 20; 27(6):785-92. PubMed ID: 22473698
    [Abstract] [Full Text] [Related]

  • 15. PIK3CA mutations in advanced cancers: characteristics and outcomes.
    Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R.
    Oncotarget; 2012 Dec 20; 3(12):1566-75. PubMed ID: 23248156
    [Abstract] [Full Text] [Related]

  • 16. Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.
    Bruckman KC, Schönleben F, Qiu W, Woo VL, Su GH.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Nov 20; 110(5):632-7. PubMed ID: 20813562
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
    Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, Samuels Y, Velculescu VE, Wang TL, Shih IeM.
    Cancer Biol Ther; 2006 Jul 20; 5(7):779-85. PubMed ID: 16721043
    [Abstract] [Full Text] [Related]

  • 19. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
    Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R.
    Mol Cancer Ther; 2013 Dec 20; 12(12):2857-63. PubMed ID: 24092809
    [Abstract] [Full Text] [Related]

  • 20. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
    Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J.
    Clin Cancer Res; 2013 Jul 01; 19(13):3533-44. PubMed ID: 23674493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.